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Abstract
Background: Andrographolide is the major labdane diterpenoid originally isolated from Andrographis paniculata
and has been shown to have anti-inflammatory and antioxidative effects. However, there is a dearth of studies on
the potential therapeutic utility of andrographolide in neuroinflammatory conditions. Here, we aimed to investigate
the mechanisms underlying andrographolide’s effect on the expression of anti-inflammatory and antioxidant heme
oxygenase-1 (HO-1) in primary astrocytes.
Methods: Measurements of the effects of andrograholide on antioxidant HO-1 and its transcription factor, Nrf2,
include gene expression, protein turnover, and activation of putative signaling regulators.
Results: Andrographolide potently activated Nrf2 and also upregulated HO-1 expression in primary astrocytes.
Andrographolide’s effects on Nrf2 seemed to be biphasic, with acute (within 1 h) reductions in Nrf2 ubiquitination
efficiency and turnover rate, followed by upregulation of Nrf2 mRNA between 8 and 24 h. The acute regulation of
Nrf2 by andrographolide seemed to be independent of Keap1 and partly mediated by p38 MAPK and ERK
signaling.
Conclusions: These data provide further insights into the mechanisms underlying andrographolide’s effects on
astrocyte-mediated antioxidant, and anti-inflammatory responses and support the further assessment of
andrographolide as a potential therapeutic for neurological conditions in which oxidative stress and
neuroinflammation are implicated.
Keywords: Andrographolide, Nrf2, Heme oxygenase 1, Astrocyte, Antioxidant response, Mitogen-activated protein
kinases
Background
Oxidative stress goes hand in hand with inflammation
and their underlying mechanisms are inextricably inter-
connected [1]. Growing evidence suggest that oxidative
stress and neuroinflammation underpin a diverse range
of CNS diseases, including stroke, traumatic brain injury,
multiple sclerosis, Alzheimer’s, Parkinson’s, and other
neurodegenerative diseases [2–5]. The brain is particu-
larly vulnerable to oxidative stress due to an abundance
of iron and polyunsaturated fatty acids which are suscep-
tible to lipid peroxidation [6, 7], thus underscoring the
importance of maintaining redox balance for normal
brain functioning. One mechanism by which the brain
defends itself against oxidative insults is via the upregu-
lation of antioxidant molecules. Interestingly, oxidative
stress strongly induces expression of heme oxygenase-1
(HO-1) in the CNS, a system not actively involved in red
blood cell metabolism [8]. Indeed, while HO-1’s primary
function is the catalysis of heme, leading to the eventual
formation of antioxidant bilirubin, carbon monoxide,
and ferrous iron (Fe2+), and in the process, prevents
heme-mediated free radical production [9], HO-1 is also
found to have anti-neuroinflammatory and neuroprotec-
tive properties in the CNS [8, 10]. Furthermore, HO-1
upregulation has been reported to be a mechanism by
which certain isoflavone metabolites protect astrocytes
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from hydrogen peroxide-induced reactive oxygen species
[11]. Together with their well-recognized roles in facili-
tating neuronal trophic support, biochemical homeosta-
sis, blood brain barrier integrity, response to
neuroinflammatory signals and scar formation, astro-
cytes play a critical role in redox homeostasis and are
the major source of antioxidant molecules and enzymes
which protect them and the neurons they support from
oxidative stresses [12, 13]. The critical involvement of
astrocytes in neuroinflammation and oxidative stress
protection as well as the pathogenicity of astrocyte dys-
regulation in various CNS diseases [14–16] gave re-
search impetus to discover and characterize novel anti-
neuroinflammatory/antioxidant therapeutics with effi-
cacy on astrocytes. Besides the aforementioned work on
isoflavone metabolites [11], a wide range of other bio-
active molecules have been studied. Of these, androgra-
pholide is a labdane diterpenoid derived from the
herbaceous Andrographis paniculata, which has been
traditionally used in Asia to treat a variety of ailments,
including fever, cough, tuberculosis, snake bites, res-
piratory tract, and urinary tract infections [17, 18].
Andrographolide has been reported to exhibit anti-
inflammatory and antioxidant activities in peripheral tis-
sues [19]. Furthermore, we have previously shown that
the brain-penetrant andrographolide attenuates IL-1β or
lipopolysaccharide-stimulated upregulation of the C–C
and C–X–C chemokines in the brain cortex as well as in
cultured astrocytes [20, 21]. However, while the efficacy
of andrographolide in reducing oxidative stress in the
CNS has been demonstrated in several studies [22–24],
the underlying molecular mechanisms have not been
thoroughly ascertained. Furthermore, andrographolide
seems to have pleiotropic effects on signaling pathways
involved in inflammatory and oxidative stress responses,
but the mechanisms underlying these effects appear dif-
ferent in various cell types [20, 21, 25–27]. In this study,
our focus is to investigate the effects of andrographolide
on HO-1 expression in astrocytes. Because HO-1 is a
known gene target of transcription factor NF-E2-related
factor 2 (Nrf2), which is critically involved in cellu-
lar defense against oxidative stress [11, 28, 29], we




Andrographolide (≥98 % purity, see Fig. 1a), cyclohexi-
mide (CHX), and other chemical reagents were
purchased from Sigma-Aldrich Ltd. (St. Louis, MO,
USA) unless otherwise specified. Various concentrations
of andrographolide, along with mitogen-activated
protein kinase (MAPK) inhibitors SB202190 and
PD98059 (Tocris Bioscience, Bristol, UK) were dissolved
in up to 0.1 % dimethyl sulfoxide (DMSO) for primary
astrocyte treatment. 0.1 % DMSO was also used as a
control (vehicle) in the cell-based assays.
Primary astrocyte culture
Primary astrocyte cultures for in vitro assays were
obtained from newborn Sprague Dawley rat pups (post-
natal days 1–3) as previously described [20]. Briefly, iso-
lated cortices were separated from the meninges in PBS,
dissociated with 0.25 % trypsin-EDTA (ThermoFisher
Scientific, Waltham, MA, USA) and filtered through a
40-μm nylon cell strainer (BD Falcon, Franklin Lakes,
NJ, USA). The resultant filtrate was centrifuged and
resuspended in DMEM/F12 media supplemented with
10 % heat-inactivated fetal bovine serum (FBS), 100 U/mL
penicillin, and 100 mg/mL streptomycin (all from
ThermoFisher Scientific, Waltham, MA, USA). After 7–
9 days of culture in a humidified atmosphere with 5 %
CO2 at 37 °C, astrocytes were enriched by vigorously shak-
ing the cell culture flasks at 350 rpm to remove non-
adherent microglial cells and oligodendrocytes. Immuno-
fluorescence staining with antibodies to glial fibrillary
acidic protein indicated the purity of the resultant astro-
cyte cultures to be >95 % (data not shown).
Cell viability assays
Rat primary astrocytes were plated onto 24-well tissue
culture plates at a density of 1 × 105 cells per well and
treated with various concentrations of andrographolide
(0–100 μM) for 24 h. Cell concentrations and viability
(recorded as % viable cells) were determined with the
Muse™ Cell Analyzer (Merck Millipore, Darmstadt,
Germany) according to manufacturer’s instructions.
Subcellular fractionation
Subcellular fractionation was performed using Nuclear
Extract kit according to manufacturer’s instructions
(Active Motif, Tokyo, Japan). Briefly, media was aspi-
rated out from 10-cm culture dishes and the cells
washed with 5 ml ice-cold phosphate-buffered saline
(PBS) with PhosSTOP™ phosphatase inhibitor cocktail
from Roche Life Science (Penzberg, Germany) and then
transferred to a prechilled conical tube. Subsequently,
the cell suspension was centrifuged at 200×g for 5 min
at 4 °C, and the resulting pellet re-suspended in hypo-
tonic buffer on ice, followed by addition of detergent
and vortexing to obtain cell lysis (checked under micro-
scope). After further centrifugation (14,000g, 30 s, 4 °C),
the supernatant (cytoplasmic fraction) was transferred
into new tubes while the pellet was re-suspended in
proprietary lysis buffer. Samples were incubated for
30 min before centrifugation (14,000g, 10 min, 4 °C).
The resulting supernatant (nuclear fraction) was
transferred to new tubes and stored frozen until use.
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Fig. 1 Dose and time-course of andrographolide’s effects on Nrf2. a Structure of andrographolide: 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-
5,8a-dimethyl-2-methylene-1-napthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone (CAS no. 5508-58-7). b Bar graphs depict mean ± S.E.M.
Nrf2 immunoreactivities (optical density, OD fold changes normalized to β-actin) in rat primary astrocytes treated with andrographolide at the
indicated concentrations for 1 h (with representative immunoblot of 3 independent experiments), with the vehicle-only (“0 μM”) group set at 1. c
Cell viability (in mean ± S.E.M. % of vehicle-only from three independent experiments) of primary astrocytes after 24 h treatment with andrographolide
at the indicated concentrations. d mRNA and e immunoreactivity changes of Nrf2 in primary astrocytes treated with andrographolide (50 μM) for the
indicated time intervals, together with immunoreactivites in the f cytosolic and g nuclear fractions (with representative immunoblots). Bar graphs show
mRNA or immunoreactivity expressed as mean ± S.E.M. fold change in transcript level or optical density (OD), respectively, with vehicle-only (“0 h”)
group set as 1, from three to four independent experiments. Raw transcript values were normalized to mean expression of housekeeping genes (see
the “Methods” section) prior to conversion to fold-change values while immunoreactivities were normalized to β-actin except for Nrf2 nuclear fractions,
which were normalized to TATA-binding protein (TBP). *p < 0.05; **p < 0.01; and ***p < 0.001; significantly different from vehicle-only group (one-way
ANOVA with Dunnett’s post hoc tests)
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Real-time PCR
For measurements of Nrf2 and HO-1 messenger RNA
(mRNA) expression, treated astrocytes were lysed in
TRIzol® reagent (ThermoFisher Scientific, Waltham,
MA, USA), precipitated, and then processed for RNA
isolation according to manufacturer’s instructions
(NucleoSpin® RNA kit from Macherey-Nagel GmbH,
Düren, Germany). After the assessment of RNA concen-
tration and purity with a NanoDrop spectrophotometer
(ThermoFisher Scientific, Waltham, MA, USA), comple-
mentary DNA (cDNA) was synthesized from RNA
samples using high-capacity cDNA reverse transcriptase
kits and quantitative real-time PCR was performed using
a Applied Biosystems® StepOnePlus™ Real-Time PCR instru-
ment (ThermoFisher Scientific, Waltham, MA, USA).
Table 1 lists the primer sequences of the genes of interest,
and fold-change values of gene expression relative to
vehicle-treated controls were computed for each experimen-
tal group using the 2−ΔΔCT formula, after the normalization
against the geometric mean of GAPDH and β-actin
expression.
Immunofluorescence imaging
Astrocytes plated on glass coverslips were treated with
andrographolide, then fixed with 4 % paraformaldehyde/
PBS for 15 min, and washed thrice with PBS followed by in-
cubation with permeabilizing buffer containing 0.1 %
Triton-X100 in PBS for 5 min at 25 °C. The cells were then
incubated in blocking solution (5 % BSA in permeabilizing
buffer) for 1 h before incubation overnight with primary
antibodies against HO-1 (1:200 dilution) in blocking solu-
tion at 4 °C. Subsequently, cells were washed thrice with
PBS and incubated with anti-mouse IgG Alexa Flour® 488
(1:400 dilution, Cell Signaling Technology, Danvers, MA,
USA) for 1 h at 25 °C. Cells were then washed with PBS be-
fore mounting the coverslips onto glass slides using mount-
ing medium containing DAPI nuclear stain (Vector
Laboratories, Burlingame, CA, USA). Immunofluorescence
images were taken with an Axioplot microscope equipped
with Carl Zeiss 510 confocal imaging scan-head and soft-
ware (Carl Zeiss MicroImaging, Jena, Germany), with the
same parameters used for all images.
Immunoblotting
Astrocytes treated with andrographolide with and
without chemical inhibitors were lysed in situ on tissue
culture plates by adding boiling Laemmli sample buffer
(Bio-Rad, Berkeley, CA, USA), heated further at 95 °C
for 5 min, then allowed to cool before electrophoretic
separation on 10 % polyacrylamide gels, transferred onto
Table 1 Primary antibodies and primers used in this study
Target Antibody Format Dilutiona Source Company
OH-1 OH-1 Rabbit polyclonal 1:1000; 1:200 (IF) Abcam
Nrf2 C-20 Rabbit polyclonal 1:1000 Santa Cruz
pS40-Nrf2 phos-Nrf2 Rabbit monoclonal 1:1000 Abcam
Nqo1 C-19 Goat polyclonal 1:1000 Santa Cruz
Keap1 E-20 Goat polyclonal 1:1000 Santa Cruz
Total Erk1/2 Erk1/2 Rabbit polyclonal 1:1000 Cell Signaling
pT202/pY204-Erk phos-Erk Rabbit polyclonal 1:1000 Cell Signaling
Total p38 p38 Rabbit polyclonal 1:1000 Cell Signaling
pT180/pY182-p38 D3F9 Rabbit monoclonal 1:1000 Cell Signaling
β-actin AC-15 Mouse monoclonal 1:5000 Sigma-Aldrich
Lamin B1 Lamin B1 Rabbit polyclonal 1:10,000 Abcam
TBP TBP Mouse monoclonal 1:5000 Abcam
Ubiquitin P4D1 Mouse monoclonal 30 μL per 1 mg lysate protein (IP)b Santa Cruz






aStated dilutions are for immunoblotting except for immunofluorescence (IF) staining and immunoprecipitation (IP). Source companies are Abcam (Cambridge,
UK); Cell Signaling Technology (Danvers, MA, USA); Santa Cruz Biotechnology (Dallas, TX, USA); and Sigma-Aldrich (St. Louis, MO, USA)
bConjugated with agarose beads (500 μg antibody/0.25 mL agarose)
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nitrocellulose membranes (ThermoFisher Scientific, Wal-
tham, MA, USA), and blocked with 5 % non-fat milk in
10 mM PBS, pH7.4 with 0.1 % Tween® 20 (PBST) at room
temperature for 1 h. Membranes were then washed and
probed with primary antibody diluted in PBST with 5 %
bovine serum albumin overnight at 4 °C. The primary
antibodies used are listed in Table 1. Following primary
antibody incubation, membranes were washed with PBST,
then incubated with horse radish peroxidase (HRP)-conju-
gated secondary antibodies (goat anti-rabbit, goat anti-
mouse, and donkey anti-goat, respectively, from Jackson
ImmunoResearch, West Grove, PA, USA), and diluted at
1:5000 for 1 h at 25 °C. To detect the proportion of phos-
phorylated protein, membranes were first probed for
phospho-proteins then stripped and reblotted for total
proteins. Immunoblots were visualized using HRP sub-
strate (Luminata™ Forte or Crescendo, Merck Millipore,
Darmstadt, Germany) and quantified by image analyzer
(UVItec Ltd., Cambridge, UK).
Immunoprecipitation
Treated astrocytes were harvested with RIPA buffer
(Santa Cruz Biotechnology, Dallas, TX, USA) supple-
mented with Complete ULTRA™ protease inhibitor
tablets and PhosSTOP™ phosphatase inhibitor (Roche
Life Science, Penzberg, Germany). The resultant lys-
ate was sonicated and centrifuged at 14,000×g for 10 min
at 4 °C, and supernatant was measured for protein
(Pierce™ Commassie kit, ThermoFisher Scientific,
Waltham, MA, USA). Input samples were prepared by
adding 70 μg protein in 1:1 ratio to boiling Laemmli sam-
ple buffer with further heating at 95 °C for 5 min. For im-
munoprecipitation, 1 mg lysate was incubated with anti-
ubiquitin monoclonal antibody-conjugated agarose beads
(Santa Cruz Biotechnology, Dallas, TX, USA) for 3 h at 4 °
C with rotation. Agarose beads were then pelleted and
washed four times with ice-cold immunoprecipitation buf-
fer (20 mM Tris-HCl pH 8, 140 mM NaCl, 2 mM
EDTA, 1 % Triton X-100), before adding Laemmli
buffer and boiling. Input samples and immunoprecipi-
tates were electrophoretically resolved on 10 and 8 %
polyacrylamide gels, respectively, then transferred
onto membranes, and immunoblotted for Nrf2 (see
above, and Table 1).
Statistical analyses
Data analyses were performed using SPSS Statistics soft-
ware (version 21, IBM Inc., Armonk, NY, USA). Dose
effects of andrographolide were compared to untreated
controls using analysis of variance (ANOVA) with
Dunnett’s post hoc tests, while other pair-wise compari-
sons of the experimental groups were performed using
ANOVA followed by Bonferroni’s post hoc tests, with
p values <0.05 considered statistically significant. All
experiments were performed independently at least
three times.
Results
Andrographolide positively regulated Nrf2 in astrocytes
To assess the potential of andrographolide to induce Nrf2,
a known regulator of HO-1 transcription [11, 28, 29], pri-
mary astrocytes were treated with various concentrations
of andrographolide for 1 h and immunoblotted with Nrf2
antibody. Interestingly, while the predicted molecular
weight of Nrf2 is around 66 kDa, there is increasing evi-
dence that the biologically relevant bands fall around 95–
110 kDa [30], and this unusual migration pattern of Nrf2
may be due to actin binding or the high acidic residue
content of Nrf2 [31, 32]. Indeed, we observed two major
bands above the 50 and 100 kDa molecular weight
markers in our immunoblots (Additional File 1: Figure S1)
and have selected the ~110 kDa bands for analyses.
Figure 1b shows that andrographolide dose-dependently
increased Nrf2 levels from as low as 1 μM, while astrocyte
viability was not significantly affected with up to 100 μM
andrographolide for 24 h (Fig. 1c).
Independent time-course of andrographolide’s effects on
Nrf2 mRNA versus protein in astrocytes
Next, we studied the time-course of both Nrf2 mRNA and
protein changes in andrographolide-treated astrocytes.
Interestingly, while treatment with andrographolide led to
an upregulation of Nrf2 mRNA, the effect was not evident
at 8 h and was only significant by 24 h (Fig. 1d). In contrast,
Nrf2 protein levels increased significantly by 30 min and
the increase was sustained throughout the study time-
course (Fig. 1e), suggesting that andrographolide-mediated
increases in Nrf2 protein levels at the acute stage (<8 h) did
not occur via the upregulation of gene expression and de
novo protein synthesis but rather may be facilitated by
changes in protein level regulation, e.g., activation or turn-
over. Furthermore, subcellular fractionation revealed that
andrographolide promoted Nrf2 accumulation in both nu-
clear and cytoplasmic compartments (Fig. 1f, g). Significant
increases of Nrf2 in nuclear fractions were observed by
30 min which coincided with early upregulation of HO-1
mRNA level (see Fig. 3a). Taken together, these data indi-
cate that andrographolide could induce HO-1 expression
acutely by promoting the accumulation of Nrf2.
Andrographolide has no effect on Nrf2 phosphorylation
or Keap1
One of the key regulators of Nrf2 is Keap1, which binds to
Nrf2 and promotes its ubiquitination and subsequent
degradation by 26S proteasome [33]. Phosphorylation of
Nrf2 at Ser40 by protein kinase C is known to disrupt Nrf2
binding to Keap1, leading to nuclear accumulation of Nrf2
[34, 35]. However, while no significant change in pSer40
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Nrf2 immunoreactivity was found, the total Nrf2 increased
with andrographolide treatment, thus resulting in a signifi-
cantly decreased ratio of pSer40 Nrf2 to total Nrf2 (Fig. 2a).
The possibility of andrographolide promoting Nrf2 protein
accumulation by altering Keap1 levels was also considered;
however, Fig. 2b showed no change in Keap1 immunoreac-
tivity with andrographolide treatment. Taken together, the
data suggest that andrographolide did not affect Nrf2 accu-
mulation by either Ser40 phosphorylation-mediated escape
from Keap1 or changes to Keap1 itself.
Andrographolide reduced Nrf2 turnover and
ubiquitination
We next studied effects of andrographolide on Nrf2 turn-
over rate. Treatment of astrocytes with cycloheximide
(CHX), which inhibits de novo protein synthesis, showed
that Nrf2 normally had a high turnover rate (half-life of
around 10 min, Fig. 2c), in agreement with previous obser-
vations [36]. With andrographolide co-treatment, how-
ever, the turnover of Nrf2 was significantly decreased,
with half-life increased to around 40 min (Fig. 2c). Since
ubiquitination signals for protein degradation, the effect of
andrographolide on levels of ubiquitinated Nrf2 was
assessed. Interestingly, ubiquitin immunoprecipitation
showed higher total Nrf2 (input protein) immunoreactiv-
ity without proportional increases in ubiquitinated Nrf2
(Fig. 2d), thus suggesting that altered Nrf2 ubiquitin effi-
ciency may be one possible mechanism by which andro-
grapholide increased Nrf2 stability and subsequent
upregulation of effector genes, including HO-1.
Fig. 2 Andrographolide increases stability of Nrf2 protein by altering ubiquitination efficiency. Primary astrocytes were treated with andrographolide
(50 μM) for the indicated time intervals and measured for immunoreactivities of a pSer40 Nrf2/total Nrf2 as well as b Keap1 immunoreactivity
normalized to β-actin (with representative immunoblots), and bar graphs showing mean ± S.E.M. fold changes in optical density (OD) with vehicle-only
(“0 h”) group set as 1. ***p < 0.001; significantly different from vehicle-only group (one-way ANOVA with Dunnett’s post hoc tests). c Rat primary
astrocytes were treated with cycloheximide (CHX, 10 μg/mL) with or without andrographolide (50 μM) co-incubation for the indicated time intervals
and then measured for total Nrf2 immunoreactivity (with representative immunoblots). The graph represents mean ± S.E.M. Nrf2 immunoreactivities in
vehicle-only (filled circles) and andrographolide co-treated (open circles) groups expressed as % of untreated (“0 h” CHX) group. *p < 0.05; significantly
different from vehicle-only group (Student’s t tests). d Rat primary astrocytes were incubated with or without 50 μM of andrographolide for 1 h and
processed for immunoprecipitation (see the “Methods” section), with representative input (IB) and ubiquitin-immunoprecipated (IP) blots for Nrf2. Bar
graph shows mean ± S.E.M. immunoreactivity (fold changes in optical densities, OD with untreated group set at 100 %) of Ub-Nrf2/total
Nrf2 normalized to β-actin. §p< 0.001 for comparison with untreated control (Student’s t tests). All data were from three to four independent experiments
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Andrographolide positively regulated HO-1 in astrocytes
As Nrf2 levels increased within 1 h of andrographolide
treatment, and therefore likely to regulate HO-1 acutely,
we performed RT-PCR and immunoblot time-course ex-
periments and showed that andrographolide (50 μM) el-
evated HO-1 mRNA and protein in a time-dependent
manner, with mRNA increase reaching statistical signifi-
cance from 2 h while increase in protein was statistically
significant from 4 h (Fig. 3a, b). These data were corrob-
orated qualitatively by immunofluorescence staining
which showed increased HO-1 immunoreactivity from
around 4 h after andrographolide treatment (Fig. 3c).
Therefore, andrographolide’s effects on HO-1 expression
may be mediated via a relatively rapid (<1 h) upregula-
tion of Nrf2. As andrographolide’s effects on antioxida-
tive pathways are unlikely to be restricted to HO-1 given
Nrf ’s regulation of multiple gene targets [29], we exam-
ined another detoxification and antioxidant molecule,
NAD(P)H quinone oxoreductase (Nqo1) [11] and found,
indeed, that andrographolide treatment also increased its
expression (Additional File 2: Figure S2). This suggests
that andrographolide’s antioxidant effect is unlikely to be
mediated by the upregulation of HO-1 only, and other
antioxidant molecules such as Nqo1 are also involved.
Upregulation of Nrf2 and HO-1 by andrographolide is
mediated by p38 MAPK- and ERK-dependent pathways
Mitogen-activated protein kinases (MAPKs) such as p38
and extracellular signal-regulated kinase (ERK) are
known to facilitate Nrf2 activation and increased expres-
sion of Nrf2 target genes [37–40], which led us to specu-
late whether andrographolide signals to these MAPKs.
Interestingly, andrograpolide dose-dependently increased
immunoreactivities of phosphorylated (activated) p38
MAPK (Fig. 4a) and p42 ERK (Fig. 4b). Furthermore,
pretreatment with inhibitors of p38 MAPK (SB202190)
or ERK (PD98059) partially attenuated the upregulation
of HO-1 mRNA by andrographolide (Fig. 4c). Similarly,
andrographolide-induced Nrf2 accumulation in both
cytoplasmic and nuclear fractions was partially attenu-
ated by pretreatment with SB202190 and PD98059
(Figs. 4d, e). These results support the involvement of
p38 MAPK and ERK signaling in regulating androgra-
pholide’s effects on Nrf2 and HO-1.
Fig. 3 Andrographolide upregulates heme oxygenase-1 in astrocytes. Primary astrocytes were treated with andrographolide (50 μM) for the
indicated time intervals and measured for HO-1 a mRNA and b immunoreactivity (with representative immunoblots), together with respective bar
graphs of mean ± S.E.M. fold changes in transcript level or optical density (OD), with vehicle-only (“0 h”) group set as 1, from three to four
independent experiments. Raw transcript values were normalized to mean expression of housekeeping genes (see the “Methods” section) prior to
conversion to fold-change values while HO-1 immunoreactivity was normalized to β-actin. **p < 0.01 and ***p < 0.001; significantly different from
vehicle-only group (one-way ANOVA with Dunnett’s post hoc tests). c Primary astrocytes treated with 50 μM andrographolide for the indicated
time intervals were processed for HO-1 immunofluorescence staining using Alexa Flour® 488-conjugated secondary antibody (green), while DAPI
counter stain (blue) was used to visualize cell nuclei. Scale bars = 50 μm
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Discussion
Neuroinflammation and oxidative stress are highly inter-
connected processes, and dysregulation of these pro-
cesses may be pathogenic in various neuroinflammatory
and neurodegenerative conditions, leading to recent re-
search efforts to uncover and assess the therapeutic po-
tential of anti-neuroinflammatory and antioxidative
compounds [1–5, 11, 41]. To this end, we have previ-
ously shown that the anti-neuroinflammatory effects of
andrographolide on astrocytes are mediated via the in-
hibition of NF-kB and c-Jun N-terminal kinase [20, 21].
In this study, our data suggest that andrographolide may
also have antioxidative effects in primary astrocytes via
the upregulation of Nrf2, a master regulator of antioxidant
responses [29]. In support of this postulate, a previous
screening of 54 bioactive compounds identified androgra-
pholide as a more potent Nrf2 activator than tert-
butylhydroquinone (tBHQ), an antioxidant frequently
used to study Nrf2/ARE activation [42]. Furthermore, we
found that HO-1, a known target of Nrf2-regulated tran-
scription and an antioxidative, cytoprotective protein in
both CNS and non-CNS cells [8–10], was also upregu-
lated in andrographolide-treated astrocytes. Here, we
showed, remarkably, that increases of HO-1 mRNA were
observable within 1 h of andrographolide incubation,
closely following the rapid accumulation (within 30 min)
of Nrf2 (Figs. 1 and 3). We subsequently found that Nrf2
increases were due to reduced Nrf2 ubiquitination effi-
ciency and turnover (Fig. 2). Taken together with observa-
tions of increased Nrf2 mRNA from between 8 to 24 h
(Fig. 1a), our data suggest that andrographolide’s effect on
Nrf2 is biphasic, with an acute effect on protein turnover
and a more intermediate effect at the transcript level. Fur-
thermore, while we focused on HO-1 in this study due to
Fig. 4 Andrographolide induces HO-1 expression through p38 MAPK- and ERK-dependent regulation of Nrf2. Effects of andrographolide on a p38 MAPK
and b ERK activation. Primary astrocytes were treated with increasing concentrations of andrographolide for 6 h and processed for immunobloting. Bar
graphs showing mean ± S.E.M. fold changes in optical density (OD, with vehicle-only “0 μM” group set as 1) of phospho-protein normalized to total protein,
***p< 0.001; significantly different from vehicle-only group (one-way ANOVA with Dunnett’s post hoc tests). c Effects of p38 MAPK and ERK inhibition on
HO-1 mRNA expression. Primary astrocytes were pretreated with or without SB202190 (p38 MAPK inhibitor) or PD98059 (MEK/ERK inhibitor) for an hour
followed by 4 h of incubation with andrographolide (with presence of inhibitors) before processing for RT-PCR. Bar graphs are mean ± S.E.M. fold change
in transcript level, with untreated group set as 1. Raw transcript values were normalized to mean expression of housekeeping genes (see the “Methods”
section) prior to conversion to fold-change values. *p< 0.05, **p< 0.01, and ***p< 0.001; significantly difference from untreated group (one-way ANOVA
followed by Dunnett’s post hoc tests.). #p< 0.05, ##p< 0.01; significantly different from 30 μM andrographolide (one- way ANOVA followed by Bonferroni’s
post hoc tests). d, e Effects of p38 MAPK and ERK inhibition on Nrf2 in the cytosolic and nuclear compartments, respectively. Primary astrocytes were
pretreated with PD98059 or SB202190 for 1 h followed by another 1 h of incubation with 30 μM andrographolide (in the presence of inhibitors).
Cytoplasmic and nuclear fractions were separated and processed for immunoblotting. Bar graphs show immunoreactivities (mean ± S.E.M. fold changes in
optical densities, OD, with untreated group set at 1) of Nrf2 normalized to β-actin (cytoplasmic) or to lamin B1 (nuclear). *p< 0.05, **p< 0.01, ***p< 0.001;
significant pairwise difference and n.s. = not significant (p> 0.05) using one-way ANOVA with Bonferroni’s post hoc tests. All data were from three to four
independent experiments
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its established anti-neuroinflammatory and neuroprotec-
tive properties in the CNS [8, 10], it is very likely that
andrographolide will upregulate other antioxidant path-
ways and molecules via Nrf2 [29], such as Nqo1, another
molecule important in the detoxification and prevention
of reactive oxygen radical formation (Additional File 2:
Figure S2).
Given that the high turnover rate of Nrf2 allows it to be
maintained at low, basal levels but be rapidly upregulated
in response to oxidative insults [33, 36, 38], we then stud-
ied potential mechanisms underlying andrographolide’s ef-
fect on Nrf2 turnover, one of which is interaction with
Keap1. Under basal conditions, Keap1 binds to the Neh2
domain of Nrf2 and sequesters it in the cytoplasm, acting
as a substrate adapter for cullin-3 (Cul3) which, together
with other proteins, forms an E3 ubiquitin ligase complex
to promote Nrf2 ubiquitination and degradation [33].
Therefore, Nrf2 may potentially escape Keap1-mediated
degradation either by downregulating Keap1 or by phos-
phorylation of Nrf2 at Ser40 which disrupts binding to
Keap1 [34, 35]. Although our finding of unchanged Keap1
and reduced rather than increased proportion of pSer40
Nrf2 (Fig. 2a, b) suggested a Keap1-independent mechan-
ism, we cannot rule out the possibility that andrographo-
lide may alter Keap1-Nrf2 association by forming adducts
with the thiol groups of reactive cysteine residues on
Keap1, similar to that reported for other Nrf2 inducers
[43]. Therefore, confirmatory studies of andrographolide’s
effects on Keap1 are required.
Nrf2 is an acidic protein with ~16 % of its total amino
acids made up of serine, threonine, and tyrosine resi-
dues, making it a probable substrate for several signaling
kinases [44]. Emerging evidence indicate that Nrf2 phos-
phorylation positively regulates its stability, as treatment
with phosphatase inhibitors led to Nrf2 hyperphosphory-
lation, accumulation, and activation of ARE-mediated
reporter gene [38]. Moreover, tBHQ and other inducers
increased Nrf2 stability and transactivation activity
through p38 MAPK and ERK [37–39]. Similarly, we found
that andrographolide activated p38 MAPK and ERK in a
dose-dependent manner (Fig. 4a, b), while inhibition of
p38 MAPK and ERK attenuated andrographolide-
mediated upregulation of HO-1 transcription as well as
Nrf2 accumulation in both cytoplasmic and nuclear com-
partments (Figs. 4c–e). Our data therefore suggest regula-
tory roles of ERK and p38 MAPK signaling in Nrf2
activation and HO-1 expression in astrocytes. It is worth
noting, however, that Nrf2 and HO-1 induction were only
partially attenuated by ERK and p38 MAPK inhibition
(Figs. 4c–e), suggesting the involvement of other signaling
molecules and pathways. Interestingly, while the two main
members of ERK, p42 ERK2, and p44 ERK1 are usually
Fig. 5 Andrographolide’s effects on Nrf2 and HO-1 in astrocytes. Summary schematic of findings of the current study. Black solid arrows indicate
positive regulation, while activation effects of andrographolide are denoted by green arrows, and inhibitory effects are denoted by red arrows. a
Andrographolide activates Nrf2 transcription between 8 and 24 h, leading to b increased Nrf2 proteins, which may also accumulate rapidly (within
1 h) through a process of altered ubiquitination which c does not alter Keap1 levels and d does not disrupt Nrf2-Keap1 binding through Ser40
phosphorylation within the Nrf2 Neh2 domain. Instead, andrographolide treatment leads to e reduced Nrf2 ubiquitination efficiency and subsequent
26S proteasomal turnover via p38 MAPK- and ERK-dependent pathways, although it is unclear whether the kinases directly act on Nrf2, or through
regulation of other signaling molecules, for, e.g., GSK-3β. Further studies are required
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co-regulated [45], andrographolide seemed to only acti-
vate p42 ERK2 (Fig. 4b), and the mechanism underlying
this specificity is unclear at present. Furthermore, there
are conflicting reports of andrographolide’s effects on sig-
naling kinases, which seemed to depend at least in part on
the cell types and time-course studied. For example, we
have found that andrographolide inhibits JNK but acti-
vates ERK and p38 MAPK in primary astrocytes (see [21]
and this study). In contrast, Lee et al. [26] showed in
human hepatoma cells that p38, but not ERK, mediated
the upregulation of Nrf2 and HO-1 by andrographolide,
while in endothelial cells, although andrographolide acti-
vated ERK, the induction of HO-1 was dependent on
phosphatidylinositol-3 kinase/protein kinase B, rather
than on ERK [27]. In the case of the hepatoma cell study
[26], the absence of ERK activation may be explained by a
relatively short time-course (2 h), while our time-course
experiments found that ERK phosphorylation was only
evident after 4 h of incubation (data not shown). These
data suggest that the molecular mechanisms underlying
andrographolide’s effects are not generalizable across cell
types, and studies are needed to characterize different
cells/tissues/systems of interest. Lastly, it is at present un-
clear whether the various signaling kinases activate Nrf2
by direct phosphorylation, or via other signaling molecules
or mechanisms. For example, p38 MAPK and ERK can in-
hibit glycogen synthase kinase-3β (GSK-3β) phosphoryl-
ation of the Neh6 domain of Nrf2, and as a result,
attenuate Keap1-independent Nrf2 ubiquitination and
degradation via the β-TrCP/Cul1 E3 ubiquitin ligase
complex [44, 46–48]. Further studies are needed to in-
vestigate whether this pathway is relevant for astrocytes
and other CNS cell types, including microglia and neurons
treated with andrographolide. These follow-up studies are
especially relevant for microglia, whose activation time-
scale is faster than astrocytes and provide the initial neu-
roinflammatory signals which subsequently activate astro-
cytes [49], and therefore also represent an essential target
in anti-neuroinflammatory therapeutics.
Conclusions
We showed in this study that andrographolide induces the
master antioxidant regulator, Nrf2, as well as one of its
target genes, HO-1, in primary astrocytes. The induction
of Nrf2 seems to be biphasic, with an acute effect (within
1 h) of reducing Nrf2 ubiquitination efficiency and subse-
quent turnover and a longer term effect (between 8 and
24 h) of upregulating Nrf2 mRNA, thus enabling the rapid
and sustained induction of HO-1. Furthermore, the acute
effects did not seem to affect Keap1 levels but may rather
be partly dependent on p38 MAPK- and ERK-mediated
signaling (Fig. 5). Given the important function of astrocytes
in mediating neuroinflammatory responses as well as main-
taining redox homeostasis in the neuronal environment, and
taking into consideration our previous work on the
anti-neuroinflammatory effects of andrgrapholide, the
current data provide further insights into the mechanisms
underlying the pleiotropic effects of andrographolide on
astrocyte-mediated antioxidant and anti-inflammatory re-
sponses, and further support the potential therapeutic utility
of andrographolide for neurological conditions characterized
by inflammation and oxidative stress. However, follow-up
studies are needed to (i) further characterize the molecular
mechanisms and signaling pathways underlying androgra-
pholide’s induction of Nrf2, both acutely and in the longer
term; (ii) uncover other antioxidant pathways and molecules
which may be affected by andrograpolide; and (iii) study the
effects of andrographolide in different CNS cell types,
including microglia and neurons, as well as in animal
models of diseases.
Additional files
Additional file 1: Figure S1. Representative immunoblots of Nrf2 in
primary astrocytes. a An example of time-point experiment after
andrographolide treatment, nuclei fraction (Fig. 1g) and b an example
of ubiquitin immunoprecipitation (IP) after andrographolide treatment
(Fig. 2d) with input lysate on the right and IP blot on the left, with
indicated molecular weight marker positions. In most cases, two
prominent bands above 50 and 100 kDa were visible, and blue arrows
indicate the bands selected for analyses (around 110 kDa) in accordance
with Lau et al. [30]. (DOCX 431 kb)
Additional file 2: Figure S2. Andrographolide upregulates NAD(P)H
quinone oxoreductase 1 (Nqo1) in astrocytes. Primary astrocytes were
treated with andrographolide (50 μM) for the indicated time intervals and
measured for Nqo1 a mRNA and b immunoreactivity (with representative
immunoblots), together with respective bar graphs of mean ± S.E.M. fold
changes in transcript level or optical density (OD), with vehicle-only
(“0 h”) group set as 1, from 4 independent experiments. Raw transcript
values were normalized to mean expression of housekeeping genes
(see the “Methods” section) prior to conversion to fold-change values
while Nqo1 immunoreactivity was normalized to β-actin. ***p < 0.001;
significantly different from vehicle-only group (one-way ANOVA with
Dunnett’s post hoc tests). (DOCX 176 kb)
Abbreviations
ANOVA: Analysis of variance; ARE: Antioxidant response element;
CHX: Cycloheximide; DAPI: 4′,6-Diamidino-2-phenylindole; DMEM:
Dulbecco’s modified Eagle medium; DMSO: Dimethyl sulfoxide;
EDTA: Ethylenediaminetetraacetic acid; ERK: Extracellular signal-regulated
kinase; FBS: Fetal bovine serum; GAPDH: Glyceraldehyde-3-phosphate
dehydrogenase; HO-1: Heme oxygenase-1; HRP: Horse radish peroxidase;
IB: Immunoblot; IP: Immunoprecipitation; Keap1: Kelch-like ECH-associated
protein 1; NF-kB: Nuclear factor-kB; Nqo1: NAD(P)H quinone oxoreductase 1;
Nrf2: Nuclear factor erythroid 2-related factor 2; OD: Optical density;
PBS: Phosphate-buffered saline; RT-PCR: Reverse transcription polymerase
chain reaction; TBP: TATA-binding protein
Acknowledgements
The authors would like to acknowledge the technical and administrative
assistance provided by Xiaoguang Xu and Wee Lee Ting.
Funding
This study was supported by a grant from the Yong Loo Lin School of
Medicine, National University of Singapore (R-184-000-223-133).
Availability of data and materials
Dataset and materials available upon request.
Wong et al. Journal of Neuroinflammation  (2016) 13:251 Page 10 of 12
Authors’ contributions
SYW designed and performed the experiments, analyzed data, and wrote
the manuscript. MGKT, PTHW, and DRH designed the experiments and
analyzed the data. MKPL initiated the study, designed the experiments,
analyzed the data, and wrote the manuscript. All authors have read, revised,
and approved the current version of the manuscript.
Competing interests
All authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was carried out according to the ARRIVE guidelines of the
National Centre for the Replacement Refinement and Reduction of Animals
in Research, and approval from the National University of Singapore’s
Institutional Animal Care and Use Committee (S13-6210) had been obtained
prior to study commencement.
Author details
1Department of Pharmacology, Yong Loo Lin School of Medicine, National
University of Singapore, Unit 09-01, Centre for Translational Medicine (MD6),
14 Medical Drive, Kent Ridge 117599, Singapore. 2Department of Clinical
Research, Singapore General Hospital, Outram, Singapore.
Received: 16 June 2016 Accepted: 15 September 2016
References
1. Dandekar A, Mendez R, Zhang K. Cross talk between ER stress, oxidative
stress, and inflammation in health and disease. Methods Mol Biol.
2015;1292:205–14.
2. Freeman LC, Ting JP. The pathogenic role of the inflammasome in
neurodegenerative diseases. J Neurochem. 2016;136 Suppl 1:29-38.
3. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s
disease. J Parkinsons Dis. 2013;3:461–91.
4. Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y,
Borlongan CV. Neuroinflammatory responses to traumatic brain injury:
etiology, clinical consequences, and therapeutic opportunities.
Neuropsychiatr Dis Treat. 2015;11:97–106.
5. Taylor JM, Main BS, Crack PJ. Neuroinflammation and oxidative stress:
co-conspirators in the pathology of Parkinson’s disease. Neurochem Int.
2013;62:803–19.
6. Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer’s disease and
Parkinson’s disease: targets for therapeutics. J Neurochem. 2016 In Press.
doi: 10.1111/jnc.13425.
7. Gandhi S, Abramov AY. Mechanism of oxidative stress in
neurodegeneration. Oxid Med Cell Longev. 2012;2012:428010.
8. Jazwa A, Cuadrado A. Targeting heme oxygenase-1 for neuroprotection
and neuroinflammation in neurodegenerative diseases. Curr Drug Targets.
2010;11:1517–31.
9. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from
basic science to therapeutic applications. Physiol Rev. 2006;86:583–650.
10. Syapin PJ. Regulation of haeme oxygenase-1 for treatment of
neuroinflammation and brain disorders. Br J Pharmacol. 2008;155:623–40.
11. Park JS, Jung JS, Jeong YH, Hyun JW, Le TK, Kim DH, Choi EC, Kim HS.
Antioxidant mechanism of isoflavone metabolites in hydrogen peroxide-
stimulated rat primary astrocytes: critical role of hemeoxygenase-1 and
NQO1 expression. J Neurochem. 2011;119:909–19.
12. Trendelenburg G, Dirnagl U. Neuroprotective role of astrocytes in cerebral
ischemia: focus on ischemic preconditioning. Glia. 2005;50:307–20.
13. Schreiner B, Romanelli E, Liberski P, Ingold-Heppner B, Sobottka-Brillout B,
Hartwig T, Chandrasekar V, Johannssen H, Zeilhofer HU, Aguzzi A, et al.
Astrocyte depletion impairs redox homeostasis and triggers neuronal loss in
the adult CNS. Cell Rep. 2015;12:1377–84.
14. Brambilla L, Martorana F, Rossi D. Astrocyte signaling and
neurodegeneration: new insights into CNS disorders. Prion. 2013;7:28–36.
15. Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and
benefits. Physiol Rev. 2014;94:1077–98.
16. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta
Neuropathol. 2010;119:7–35.
17. Chao WW, Lin BF. Isolation and identification of bioactive compounds in
Andrographis paniculata (Chuanxinlian). Chin Med. 2010;5:17.
18. Panossian A, Davtyan T, Gukassyan N, Gukasova G, Mamikonyan G,
Gabrielian E, Wikman G. Effect of andrographolide and Kan Jang—fixed
combination of extract SHA-10 and extract SHE-3—on proliferation of
human lymphocytes, production of cytokines and immune activation
markers in the whole blood cells culture. Phytomedicine.
2002;9:598–605.
19. Lim JC, Chan TK, Ng DS, Sagineedu SR, Stanslas J, Wong WS. Andrographolide
and its analogues: versatile bioactive molecules for combating inflammation
and cancer. Clin Exp Pharmacol Physiol. 2012;39:300–10.
20. Wong SY, Chan SJ, Wong WS, Wong PT, Lai MK. Andrographolide
attenuates interleukin-1b-stimulated upregulation of chemokine CCL5 and
glial fibrillary acidic protein in astrocytes. Neuroreport. 2014;25:881–6.
21. Wong SY, Tan MG, Banks WA, Wong WS, Wong PT, Lai MK. Andrographolide
attenuates LPS-stimulated up-regulation of C-C and C-X-C motif chemokines in
rodent cortex and primary astrocytes. J Neuroinflammation. 2016;13:34.
22. Zhang Z, Lai D, Wang L, Yu P, Zhu L, Guo B, Xu L, Zhou L, Sun Y, Lee SM,
Wang Y. Neuroprotective effects of the andrographolide analogue AL-1 in
the MPP(+)/MPTP-induced Parkinson’s disease model in vitro and in mice.
Pharmacol Biochem Behav. 2014;122:191–202.
23. Chern CM, Liou KT, Wang YH, Liao JF, Yen JC, Shen YC. Andrographolide
inhibits PI3K/AKT-dependent NOX2 and iNOS expression protecting mice
against hypoxia/ischemia-induced oxidative brain injury. Planta Med.
2011;77:1669–79.
24. Das S, Gautam N, Dey SK, Maiti T, Roy S. Oxidative stress in the brain of
nicotine-induced toxicity: protective role of Andrographis paniculata Nees
and vitamin E. Appl Physiol Nutr Metab. 2009;34:124–35.
25. Hsieh CY, Hsu MJ, Hsiao G, Wang YH, Huang CW, Chen SW, Jayakumar T, Chiu
PT, Chiu YH, Sheu JR. Andrographolide enhances nuclear factor-kB subunit p65
Ser536 dephosphorylation through activation of protein phosphatase 2A in
vascular smooth muscle cells. J Biol Chem. 2011;286:5942–55.
26. Lee JC, Tseng CK, Young KC, Sun HY, Wang SW, Chen WC, Lin CK, Wu YH.
Andrographolide exerts anti-hepatitis C virus activity by up-regulating
haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma
cells. Br J Pharmacol. 2014;171:237–52.
27. Lu WJ, Lee JJ, Chou DS, Jayakumar T, Fong TH, Hsiao G, Sheu JR. A novel
role of andrographolide, an NF-kB inhibitor, on inhibition of platelet
activation: the pivotal mechanisms of endothelial nitric oxide synthase/
cyclic GMP. J Mol Med (Berl). 2011;89:1261–73.
28. Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway:
Keap1-dependent and -independent mechanisms of regulation. Biochem
Pharmacol. 2013;85:705–17.
29. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol
Toxicol. 2013;53:401–26.
30. Lau A, Tian W, Whitman SA, Zhang DD. The predicted molecular weight of
Nrf2: it is what it is not. Antioxid Redox Signal. 2013;18:91–3.
31. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2
(Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to
the tandem NF-E2/AP1 repeat of the b-globin locus control region. Proc
Natl Acad Sci U S A. 1994;91:9926–30.
32. Kang KW, Lee SJ, Park JW, Kim SG. Phosphatidylinositol 3-kinase regulates
nuclear translocation of NF-E2-related factor 2 through actin rearrangement
in response to oxidative stress. Mol Pharmacol. 2002;62:1001–10.
33. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription
factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol.
2005;25:162–71.
34. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by
protein kinase C regulates antioxidant response element-mediated
transcription. J Biol Chem. 2002;277:42769–74.
35. Niture SK, Jain AK, Jaiswal AK. Antioxidant-induced modification of INrf2
cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are
both required for stabilization and nuclear translocation of Nrf2 and
increased drug resistance. J Cell Sci. 2009;122:4452–64.
36. Stewart D, Killeen E, Naquin R, Alam S, Alam J. Degradation of transcription
factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by
cadmium. J Biol Chem. 2003;278:2396–402.
37. Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C, Han J, Agarwal A, Kong AN.
Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated
Wong et al. Journal of Neuroinflammation  (2016) 13:251 Page 11 of 12
protein kinase isoforms contributing to the induction of antioxidant
response element-mediated heme oxygenase-1 in human hepatoma
HepG2 cells. Cancer Res. 2006;66:8804–13.
38. Nguyen T, Sherratt PJ, Huang HC, Yang CS, Pickett CB. Increased protein
stability as a mechanism that enhances Nrf2-mediated transcriptional
activation of the antioxidant response element. Degradation of Nrf2 by the
26 S proteasome. J Biol Chem. 2003;278:4536–41.
39. Zipper LM, Mulcahy RT. Inhibition of ERK and p38 MAP kinases inhibits
binding of Nrf2 and induction of GCS genes. Biochem Biophys Res
Commun. 2000;278:484–92.
40. Eom HJ, Choi J. Oxidative stress of CeO2 nanoparticles via p38-Nrf-2
signaling pathway in human bronchial epithelial cell, Beas-2B. Toxicol Lett.
2009;187:77–83.
41. Han Z, Li L, Wang L, Degos V, Maze M, Su H. a7 nicotinic acetylcholine
receptor agonist treatment reduces neuroinflammation, oxidative stress, and
brain injury in mice with ischemic stroke and bone fracture. J Neurochem.
2014;131:498–508.
42. Wu KC, McDonald PR, Liu J, Klaassen CD. Screening of natural compounds
as activators of the keap1-nrf2 pathway. Planta Med. 2014;80:97–104.
43. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y,
Yamamoto M, Talalay P. Direct evidence that sulfhydryl groups of Keap1 are
the sensors regulating induction of phase 2 enzymes that protect against
carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002;99:11908–13.
44. Rojo AI, Medina-Campos ON, Rada P, Zuniga-Toala A, Lopez-Gazcon A,
Espada S, Pedraza-Chaverri J, Cuadrado A. Signaling pathways activated by
the phytochemical nordihydroguaiaretic acid contribute to a Keap1-
independent regulation of Nrf2 stability: role of glycogen synthase kinase-3.
Free Radic Biol Med. 2012;52:473–87.
45. Houslay MD, Kolch W. Cell-type specific integration of cross-talk between
extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol.
2000;58:659–68.
46. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements
JL, Sabio G, Davis RJ, Matthews DE, Doble B, Rincon M. Phosphorylation
by p38 MAPK as an alternative pathway for GSK3b inactivation. Science.
2008;320:667–70.
47. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y,
Li Z, et al. Erk associates with and primes GSK-3β for its inactivation
resulting in upregulation of beta-catenin. Mol Cell. 2005;19:159–70.
48. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/β-
TrCP promotes glycogen synthase kinase 3-dependent degradation of the
Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol.
2011;31:1121–33.
49. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2
microglia: the good, the bad, and the inflamed. J Neuroinflammation.
2014;11:98.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wong et al. Journal of Neuroinflammation  (2016) 13:251 Page 12 of 12
